Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2002; 88(04): 688-689
DOI: 10.1055/s-0037-1613278
DOI: 10.1055/s-0037-1613278
Letters to the Editor
High Plasma Levels of Lipoprotein(a) in Uremic Patients are Related to Markers of Inflammation, and to Activated, not Impaired, Fibrinolysis
Further Information
Publication History
Received
14 March 2002
Accepted
21 May 2002
Publication Date:
09 December 2017 (online)
-
References
- 1 Dahlen GH, Stenlund H. Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance. Clin Genet 1997; 52: 272-80.
- 2 Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis 1996; 27: 1-25.
- 3 Hajjar K, Gavish D, Breslow J, Nachman R. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339: 303-5.
- 4 Grainger D, Kirschenlohr H, Metcalfe J, Wiessberg P, Wade D, Lawn R. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993; 260: 1655-8.
- 5 Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, Broze Jr GJ, Simari RD. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 2001; 98: 2980-7.
- 6 Ledue TB, Neveux LM, Palomaki GE, Ritchie RF, Craig WY. The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response. Clin Chim Acta 1993; 223: 73-82.
- 7 Noma A, Abe A, Maeda S, Seishima M, Makino K, Yano Y, Shimokawa K. Lp(a): an acute-phase reactant?. Chem Phys Lipids 1994; 67-68: 411-7.
- 8 Mezzano D, Tagle R, Panes O, Perez M, Downey P, Muñoz B, Aranda E, Barja P, Thambo S, González F, Mezzano S, Pereira J. Hemostatic disorder in uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 1996; 76: 312-21.
- 9 Mezzano D, Pais EO, Aranda E, Panes O, Downey P, Ortiz M, Tagle R, González F, Quiroga T, Cáceres MS, Leighton F, Pereira J. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endotelial dysfunction in uremia. Kidney Int 2001; 60: 1844-50.
- 10 Kario K, Matsuo T, Kobayashi H, Matsuo M, Asada R, Koide M. High lipoprotein(a) levels in chronic hemodialysis patients are closely related to the acute phase reaction. Thromb Haemost 1995; 74: 1020-4.
- 11 Hervio L, Girard-Globa A, Durlach V, Angles-Cano E. The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin. Eur J Clin Invest 1996; 26: 411-7.
- 12 Falco C, Estelles A, Dalmau J, Espana F, Aznar J. Influence of lipoprotein(a) levels and isoforms on fibrinolytic activity: study in families with high lipoprotein(a) levels. Thromb Haemost 1998; 79: 818-23.
- 13 Halvorsen S, Skjonsberg OH, Berg K, Ruyter R, Godal HC. Does Lp(a) lipoprotein inhibit the fibrinolytic system?. Thromb Res 1992; 68: 223-32.
- 14 Lu H, Bruckert J, Soria J, Li H, de Gennes JL, Legrand A, Peynet J, Soria C. Absence of inhibition by lipoprotein(a) inhibition of tPA induced thrombolysis in a patient’s plasma milieu. Blood Coagul Fibrinolysis 1990; 01: 513-6.
- 15 Mao SJ, Tucci MA. Lipoprotein(a) enhances plasma clot lysis in vitro. FEBS Lett 1990; 267: 131-4.
- 16 Liu JN, Harpel PC, Pannell R, Gurevich V. Lipoprotein(a): a kinetic study of its influence on fibrin-dependent plasminogen activation by prourokinase or tissue plasminogen activator. Biochemistry 1993; 32: 9694-700.